INC Research Promotes Medical and Oncology Expertise in Support of "Building Bridges to Conquer Cancer" Initiative at 2013 ASCO Annual Meeting
(Thomson Reuters ONE) -
Global CRO Offers Specialist Teams for Oncology Drug Development
Raleigh, N.C., May 31, 2013 - INC Research, LLC, a therapeutically focused
global clinical research organization (CRO) with a Trusted Process® for
delivering reliable results, is attending the 2013 American Society of Clinical
Oncology (ASCO) Annual Meeting from May 31 - June 4 in Chicago to discuss
accelerating development in the quest to conquer cancer.
"We are excited to be taking part once again in this year's ASCO and its
'Building Bridges to Conquer Cancer' initiative," said Nicholas Kenny, PhD,
Executive Vice President and General Manager, Global Oncology and Hematology at
INC Research. "The pace of drug development is increasing, driving greater
opportunity for patients, but also increased scrutiny and competition for the
most critical clinical trials. With specialists located worldwide, INC Research
provides biopharmaceutical companies access to the most appropriate patient
populations and study sites to accelerate development from first in patient
Phase I studies through to approval, ultimately leading to more widely
available, and better, cancer treatments."
Since 2001, INC Research has played a lead role alongside biopharmaceutical
companies worldwide in conducting cancer clinical trials and has active oncology
clinical trials underway in more than 40 countries involving a team of 400
specialists focused exclusively on oncology clinical research. INC Research
provides medical, surgical and radiation oncologists with experience in all
major and rare solid tumor types, along with specialist teams for early phase
oncology development and hematological malignancies. INC Research supports all
levels and stages of clinical development with the full spectrum of Phase I to
IV oncology services, as well as extensive early phase experience with
innovative drugs and protocols, including Phase I/IIa transitional programs.
For more information about how INC Research's oncology research capabilities are
bridging the gap between patients and better cancer treatments, please visit
Booth # 20121 at ASCO or download our oncology fact sheet.
About INC Research
INC Research is a therapeutically focused clinical research organization with a
high-performance reputation for conducting global clinical development programs
of the highest integrity. Pharmaceutical and biotechnology companies look to us
for a complete range of customized Phase I to IV programs in all therapeutic
areas and patient populations (including pediatric and women's health). Our
Trusted Process® methodology and therapeutic foresight lead customers to better-
informed product development decisions, while our solid site relationships are a
critical success factor in delivering clinical trial results on time and on
budget. INC was ranked "Top CRO" by sites worldwide in the 2013 CenterWatch
Global Investigative Site Relationship Survey. INC Research is headquartered in
Raleigh, NC. For more information, please visit www.incresearch.com or follow us
at (at)inc_research.
Contact: Lori Dorer, Media +1 (513) 345-1685
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: INC RESEARCH, LLC via Thomson Reuters ONE
[HUG#1706380]
Unternehmensinformation / Kurzprofil:
Datum: 31.05.2013 - 16:21 Uhr
Sprache: Deutsch
News-ID 265316
Anzahl Zeichen: 3984
contact information:
Town:
Raleigh
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 197 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"INC Research Promotes Medical and Oncology Expertise in Support of "Building Bridges to Conquer Cancer" Initiative at 2013 ASCO Annual Meeting"
steht unter der journalistisch-redaktionellen Verantwortung von
INC RESEARCH, LLC (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
